Valuation : Fortress Biotech, Inc.

Market Cap 92.38M 79.61M 74.64M 68.13M 128M 8.83B 129M 886M 346M 4.46B 347M 339M 14.78B P/E 2026 *
1.09x
P/E 2027 * -2.77x
Enterprise Value 92.38M 79.61M 74.64M 68.13M 128M 8.83B 129M 886M 346M 4.46B 347M 339M 14.78B EV / Sales 2026 *
1.17x
EV / Sales 2027 * 0.82x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week-3.48%
Current month-11.50%
1 month-17.31%
3 months-1.07%
6 months-19.01%
Current year-24.32%
1 week 2.74
Extreme 2.745
2.99
1 month 2.57
Extreme 2.57
3.28
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.25
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
1/4/26 Free

Chief Financial Officer

2,967 0.0096%
18/3/26 Free

Chief Executive Officer

475,424 1.5318%
18/3/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-3.48%+7.36%-52.65% 92.38M
-1.67%-4.78%+36.76%-4.34% 79.3B
-0.90%+2.39%-19.06%-35.50% 59.21B
-3.35%-4.92%+472.81%+18.97% 55.09B
-6.78%-4.19%-3.45%+28.35% 49.86B
-2.43%-2.35%+8.33%+160.40% 47.9B
-1.35%+0.79%+65.25%-18.47% 32.28B
-2.64%-2.69%+46.99%+92.55% 25.21B
-0.09%+4.98%+11.00%+199.86% 23.87B
-0.34%+1.35%+62.33%+122.21% 16.89B
Average -2.06%-1.42%+68.83%+51.14% 38.97B
Weighted average by Cap. -2.42%-2.05%+83.83%+41.73%

Financials

2026 *2027 *
Net sales 78.79M 67.9M 63.66M 58.11M 109M 7.53B 110M 755M 295M 3.8B 296M 289M 12.6B 113M 97.59M 91.5M 83.52M 157M 10.82B 158M 1.09B 424M 5.46B 425M 416M 18.12B
Net income 88.25M 76.04M 71.3M 65.08M 123M 8.43B 123M 846M 330M 4.26B 331M 324M 14.12B -37.81M -32.58M -30.55M -27.89M -52.54M -3.61B -52.71M -362M -141M -1.82B -142M -139M -6.05B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
28/08/26 USD 2.770 -1.07% 309,687
27/08/26 USD 2.800 -0.36% 463,476
26/08/26 USD 2.810 -0.71% 395,827
25/08/26 USD 2.830 -3.41% 451,342
24/08/26 USD 2.930 +2.09% 603,896
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.770USD
Average target price
11.00USD
Spread / Average Target
+297.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock